Century Therapeutics’ (IPSC) Buy Rating Reiterated at Guggenheim

Guggenheim restated their buy rating on shares of Century Therapeutics (NASDAQ:IPSC) in a report issued on Friday,Benzinga reports.

Other equities research analysts have also issued reports about the company. Chardan Capital cut their price objective on Century Therapeutics from $11.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, March 24th. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of Century Therapeutics in a research note on Wednesday, January 22nd. Finally, Piper Sandler decreased their price objective on Century Therapeutics from $4.00 to $2.00 and set an “overweight” rating on the stock in a report on Thursday, March 20th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $5.00.

Century Therapeutics Price Performance

Shares of IPSC stock opened at $0.51 on Friday. The stock has a 50 day simple moving average of $0.71 and a 200-day simple moving average of $1.12. Century Therapeutics has a 1-year low of $0.51 and a 1-year high of $4.43. The company has a market cap of $44.13 million, a price-to-earnings ratio of -0.28 and a beta of 1.75.

Century Therapeutics (NASDAQ:IPSC) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.02. The business had revenue of $4.18 million for the quarter, compared to the consensus estimate of $0.67 million. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. Analysts anticipate that Century Therapeutics will post -1.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Century Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Marshall Wace LLP purchased a new stake in Century Therapeutics in the 4th quarter valued at $36,000. Jane Street Group LLC grew its holdings in shares of Century Therapeutics by 166.2% in the fourth quarter. Jane Street Group LLC now owns 48,036 shares of the company’s stock valued at $49,000 after purchasing an additional 29,992 shares during the period. Two Sigma Advisers LP acquired a new stake in Century Therapeutics during the fourth quarter worth about $52,000. Sei Investments Co. purchased a new position in Century Therapeutics during the fourth quarter worth about $53,000. Finally, Barclays PLC boosted its holdings in Century Therapeutics by 283.6% in the 3rd quarter. Barclays PLC now owns 61,945 shares of the company’s stock valued at $106,000 after purchasing an additional 45,797 shares during the last quarter. Institutional investors and hedge funds own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.